Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK

BACKGROUND: Interleukin-17A (IL-17A) antagonists are a recent innovation for treating psoriatic arthritis (PsA). There are currently no cost-effectiveness analyses (CEAs) comparing the IL-17A antagonists ixekizumab and secukinumab in PsA from a UK perspective. OBJECTIVE: We conducted a CEA from the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmacoecon Open
Autors principals: Schweikert, Bernd, Malmberg, Chiara, Åkerborg, Örjan, Kumar, Gayathri, Nott, Debby, Kiri, Sandeep, Sapin, Christophe, Hartz, Susanne
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2020
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7688884/
https://ncbi.nlm.nih.gov/pubmed/32166657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-020-00202-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars